Alimera Sciences (NASDAQ:ALIM – Get Rating) had its price objective decreased by equities research analysts at HC Wainwright from $10.00 to $8.00 in a report issued on Tuesday, The Fly reports. HC Wainwright’s price objective suggests a potential upside of 58.42% from the company’s current price.
Several other analysts have also issued reports on the stock. Zacks Investment Research raised shares of Alimera Sciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 27th. Alliance Global Partners cut their target price on shares of Alimera Sciences from $14.50 to $11.00 in a research note on Friday, February 25th. Finally, StockNews.com initiated coverage on shares of Alimera Sciences in a research note on Thursday, May 5th. They issued a “hold” rating for the company.
NASDAQ ALIM opened at $5.05 on Tuesday. The firm’s fifty day moving average price is $5.56 and its two-hundred day moving average price is $5.11. Alimera Sciences has a 1 year low of $3.94 and a 1 year high of $10.50. The firm has a market capitalization of $35.31 million, a P/E ratio of -6.39 and a beta of 1.48.
Several institutional investors have recently made changes to their positions in ALIM. Millennium Management LLC bought a new stake in Alimera Sciences during the 4th quarter worth approximately $65,000. Ensign Peak Advisors Inc acquired a new position in shares of Alimera Sciences in the 3rd quarter worth approximately $81,000. Finally, Morgan Stanley lifted its position in shares of Alimera Sciences by 0.7% in the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock worth $3,896,000 after purchasing an additional 2,797 shares during the period. 40.97% of the stock is currently owned by institutional investors.
Alimera Sciences Company Profile (Get Rating)
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- The Low In Lordstown Motors May Not Be The Last
- Follow The Money To Cigna
- Intuitive Surgical is an Intuitive Buy
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Time to Buy These 3 Oversold Mid-Caps
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.